Evidence map›Paper›PMID 40574323›Full record

ReviewHuman reproduction update2025

Protein O-GlcNAcylation in reproductive biology and the impact of metabolic disease.

Atalie L Scrivener, Melissa Westwood, Peter T Ruane, John D Aplin

Abstract readReview
In one paragraph

Review in Human reproduction update, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Atalie L ScrivenerMaternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St. Mary's Hospital, Manchester, UK.ORCID 0000-0002-3542-4132
Melissa WestwoodMaternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St. Mary's Hospital, Manchester, UK.
Peter T RuaneMaternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St. Mary's Hospital, Manchester, UK.ORCID 0000-0002-1476-1666
John D AplinMaternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St. Mary's Hospital, Manchester, UK.ORCID 0000-0001-8777-9261

Funding

Medical Research Council PhD Studentship
6 · The paper itself

Abstract

backgroundProtein O-GlcNAcylation is a reversible post-translational modification which regulates the function of thousands of proteins to control generic and cell type-specific actions. O-GlcNAc addition and removal downstream of the hexosamine biosynthetic pathway (HBP) is mediated by only two enzymes: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), respectively. Crucially, O-GlcNAcylation provides a regulatory layer to protein function that is responsive to metabolic status and thus metabolic disease impinges on this system. Animal and ex vivo models show that O-GlcNAcylation is important for peri-conceptual and pregnancy processes. OBJECTIVE AND RATIONALE: Fundamental knowledge about O-GlcNAcylation of proteins involved in reproductive processes is lacking. Here, we give relevant, and mechanistically well understood, examples of how protein O-GlcNAcylation can affect cellular processes and examine available data on germ cells, embryonic development, endometrial receptivity, and placentation. OGT and OGA regulation are placed within the wider context of reproductive biology. We also highlight gaps in knowledge and suggest avenues for next-phase research. SEARCH

methodsPubMed and Google Scholar (2013-2024) were interrogated, including only publications in English. Search terms included: GlcNAc AND Oocyte, GlcNAc AND Sperm, GlcNAc AND Embryo, GlcNAc AND Cell Differentiation, GlcNAc AND Endometrium, GlcNAc AND Endometrial Receptivity, GlcNAc AND Placenta, GlcNAc AND diabetes, and GlcNAc AND obesity. OUTCOMES: Some evidence for the global impact of O-GlcNAcylation in maturation of oocytes and sperm, pre-implantation development, implantation, and placentation has been gathered by pharmacological inhibition and/or targeted mutagenesis of OGT and OGA. Blocking or inactivating OGT gives an embryonic lethal phenotype in most species. Mouse embryos can tolerate inactivation of OGA, but the offspring are growth-restricted and die postnatally. In general, HBP utilization in pre-implantation differs between species. This is likely to be the case in post-implantation development too, but it is already clear from stem cell biology that O-GlcNAcylation is important in the differentiation of most embryonic cell lineages including neurones, osteoclasts, enterocytes, and adipocytes. The identification of the progesterone receptor as an OGT target suggests important and widespread involvement of O-GlcNAcylation in reproductive processes. In the adult endometrium, protein O-GlcNAcylation decreases during decidualization, however, there is some evidence to suggest that O-GlcNAcylation of specific proteins promotes receptivity to the implanting embryo. In placenta, key aspects of development (e.g. angiogenesis) and function (e.g. transport, hormone production) are influenced by O-GlcNAcylation. Hyperglycaemia-induced changes in protein O-GlcNAcylation have negative impacts throughout reproductive systems and while there is less information on the consequences of lipid-mediated alterations to this post-translational modification, available evidence points to skewed protein O-GlcNAcylation contributing to impaired reproductive function in individuals living with obesity. WIDER IMPLICATIONS: This review highlights protein O-GlcNAcylation as a regulator of reproductive processes and identifies large knowledge gaps which must be filled to improve fundamental understanding. Targeting O-GlcNAcylation regulatory networks, including acceptor site mutagenesis, in defined cell populations of reproductive tissues will advance knowledge. The interface of O-GlcNAcylation with metabolic disease needs disentangling to determine how interventions to alleviate disease impact reproductive outcomes. REGISTRATION NUMBER: N/A.

Indexed as

Metabolic DiseasesN-AcetylglucosaminyltransferasesProtein Processing, Post-TranslationalReproductionAnimalsbeta-N-AcetylhexosaminidasesEmbryonic DevelopmentFemaleHumansMalePregnancybeta-N-AcetylhexosaminidasesN-AcetylglucosaminyltransferasesO-GlcNAc transferaseembryoendometriumGlcNAcOGAOGToocyteovaryplacentaspermstem cells

Identifiers

PMID40574323
PMCPMC12405617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.